标题:Progress of HDAC inhibitor panobinostat in the treatment of cancer
作者:Li,X.;Zhang,J.;Xie,Y.;Jiang,Y.;Yingjie,Z.;Xu,W.
作者机构:[Li, X] Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Shandong University, 44 West Culture Road, 250012 Ji'nan, Shandong, Chin 更多
通讯作者:Zhang, YJ
通讯作者地址:[Zhang, YJ]Shandong Univ, Dept Med Chem, Sch Pharmaceut Sci, 44 West Culture Rd, Jinan 250012, Shandong, Peoples R China.
来源:Current drug targets-The International journal for timely in-depth reviews on drug targets
出版年:2014
卷:15
期:6
页码:622-634
DOI:10.2174/1389450115666140306152642
关键词:Combined therapy;Hematologic malignancies;Histone deacetylase inhibitors;Monotherapy;Panobinostat;Solid tumors
摘要:Histone deacetylases are a class of enzymes that play important roles in post translational modifications of histones by deacetylating the lysine residues as well as interacting with various non-histone proteins. This type of enzymes is closely related to oncogenesis and has been proved to be attractive targets for designing novel anti-cancer agents. Over the last 10 years, a large number of HDACs have entered pre-clinical and/or clinical trials. Among these drug candidates, the pan-HDAC inhibitor, panobinostat demonstrated high therapeutic potential as monotherapy and combined therapy in both preclinical models and clinical cancer patients. In this review, we have mainly focused on the recent progress of the clinical studies about panobinostat, and discussed its anti-cancer effects and molecular rationale for the treatment strategies.
收录类别:SCOPUS;SCIE
WOS核心被引频次:19
Scopus被引频次:21
资源类型:期刊论文
原文链接:https://www.scopus.com/inward/record.uri?eid=2-s2.0-84899844914&doi=10.2174%2f1389450115666140306152642&partnerID=40&md5=0495871cff739e4b0dcb21cb2217321f
TOP